Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
2008-04-01
2008-04-01
Foley, Shanon (Department: 1642)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C435S328000, C435S330000, C530S387100, C530S387300, C530S387700, C530S387900
Reexamination Certificate
active
07351583
ABSTRACT:
A novel gene (designated PHOR-1) that is highly over-expressed in prostate and other cancers and its encoded protein are described. PHOR-1 is a G protein-coupled receptor with homology to receptors involved in olfaction. PHOR-1 in normal human tissues is restricted to prostate, and this gene is highly over-expressed in prostate cancer as well as in cancers of the kidney, uterus, cervix, stomach and rectum. Consequently, PHOR-1 provides a diagnostic and/or therapeutic target for prostate cancer.
REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 5756309 (1998-05-01), Soppet et al.
patent: 5795572 (1998-08-01), Diegel et al.
patent: 5844093 (1998-12-01), Kettleborough et al.
patent: 5948890 (1999-09-01), Soppet et al.
patent: 6800746 (2004-10-01), Xu et al.
patent: 2002/0022248 (2002-02-01), Xu et al.
patent: 2002/0192763 (2002-12-01), Xu et al.
patent: 2003/0022237 (2003-01-01), Feder et al.
patent: 2003/0088059 (2003-05-01), Zozula
patent: 2003/0113798 (2003-06-01), Burmer et al.
patent: 2003/0213004 (2003-11-01), Jakobovits et al.
patent: 1074617 (2001-02-01), None
patent: 1270724 (2003-01-01), None
patent: 2211504 (1989-07-01), None
patent: WO-93/17715 (1993-09-01), None
patent: WO-96/39435 (1996-12-01), None
patent: WO-97/25426 (1997-07-01), None
patent: WO-99/06550 (1999-02-01), None
patent: WO-00/04149 (2000-01-01), None
patent: WO-00/20590 (2000-04-01), None
patent: WO-01/22920 (2001-04-01), None
patent: WO-01/25272 (2001-04-01), None
patent: WO-01/25434 (2001-04-01), None
patent: WO-01/27158 (2001-04-01), None
patent: WO-02/28899 (2001-04-01), None
patent: WO-02/30268 (2001-04-01), None
patent: WO-01/31014 (2001-05-01), None
patent: WO-01/34802 (2001-05-01), None
patent: WO-01/39798 (2001-06-01), None
patent: WO-01/51633 (2001-07-01), None
patent: WO-01/57188 (2001-08-01), None
patent: WO-01/60860 (2001-08-01), None
patent: WO-01/68805 (2001-09-01), None
patent: WO-01/73032 (2001-10-01), None
patent: WO-01/74904 (2001-10-01), None
patent: WO-01/98526 (2001-12-01), None
patent: WO-02/16548 (2002-02-01), None
patent: WO-02/24726 (2002-03-01), None
patent: WO-02/031087 (2002-08-01), None
patent: WO-02/089747 (2002-11-01), None
patent: WO-02/092842 (2002-11-01), None
Banki et al, 1994, JBC, 269 (4): 2847-51.
Bendayan et al, 1995, J Histochem Cytochem, 43(9): 881-886).
Alberts et al., Molecular Biology of the Cell, 3rd Edition (1994) p. 465.
Bepler et al., Genomics (1999) 55(2):164-175.
Birnbaumer, Cell (1992) 71:1069.
Boon, Adv. Can. Res. (1992) 58:177-210.
Bowie et al., Science (1990) 257:1306-1310.
Burgess et al., Journal of Cell Biology (1990) 11:2129-2138.
Burmer, Environmental Health Perspectives (1991) 93:27-31.
Busken et al., Digestive Disease Week Abstracts and Itinerary Planner (2003) abstract No. 850.
Chang et al., Leukemia (2003) 17:1263-1293.
Craft et al., Cancer Res. (1999) 59:5030-036.
Crystal, Science (1995) 270:404-410.
Curti, Crit. Rev. in Oncology/Hematology (1993) 14:29-39.
Deonarain, Expert Opin. Ther. Pat. (1998) 8:53-69.
EMBL Sequence Accession No. A06681.Gcq—Geneseq—D, Jun. 13, 2000 (first entry).
EMBL Sequence Accession No. AF101565, Jan. 29, 1999, Nov. 8, 2000.
Evans et al., Am. J. Obstet. Gynecol. (1994) 171(4):1055-1057.
Ezzell, J. NIH Res. (1995) 7:46-49.
Fu et al., EMBO Journal (1996) 15:4392-4401.
Gillies et al., Human Antibodies and Hybridomas (1990) 1(1):47-54.
Greenspan et al., Nature Biotechnology (1999) 7:936-937.
Greulich and Erikson, J. Biol. Chem. (1998) 273:13280.
Gura, Science (1997) 278:1041-1042.
Harrison, Immunol Series 49:411-464.
Hartwell et al., Science (1997) 278:1064-1068.
Herbert et al., The Dictionary of Immunology, Academic Press, 4thedition, 1995, p. 58.
Holmes, Exp. Opin. Invest. Drugs (2001) 10:511-519.
Hubert et al., Proc. Natl. Acad. Sci. USA (1999) 96(25):14523-14528.
Hummler et al., PNAS USA (1994) 91:5647-5661.
International Search Report for PCT/US02/15520, mailed on Oct. 20, 2004, 4 pages.
Jain, Sci. Am. (1994) 271:58-65.
Jansen, Pediatric Res. (1995) 37(6):681-686.
Klein et al., Nat. Med. (1997) 3:402.
Lai et al., Clin. Cancer Res. (2000) 6(8):3172-3176.
Lazar et al., Molecular and Cell Biology (1988) 8:1247-1252.
Liebmann and Bohmer, Curr. Med. Chem. (2000) 7:911.
Malnic et al., Cell (1999) 96:713.
Maniatis et al. (Eds.), Mol. Cloning (1989) Cold Spring Laboratory, Cold Spring Harbor, p. 17.31.
Maudsley et al., J. Biol. Chem. (2000) 275:9572.
McLean and Hill, Eur. J. of Cancer (1993) 29A:2243-2248.
Miller, FASEB J. (1995) 9:190-199.
Montesano et al., Int'l J. Cancer (1996) 69:225-235.
Muller et al., MCB (1991) 11:1785.
NAGENESEQ, EMBL Sequence Accession No. X40518, Jun. 18, 1999 (first entry).
Oya and Schulz, Br. J. Cancer (2000) 83(5):626-631.
Pinto et al., Clin. Cancer Res. (1996) 2(9):1445-1451.
Raming et al., Nature (1993) 361:353.
Raming et al., Receptor Channels (1998) 6:141.
Rampsrch Granli Reports, pp. 2-5, earli, 2002.
Reiter et al., Proc. Natl. Acad. Sci. USA (1998) 95:1735.
Rogers et al. Bioscience Reports (1988) 8:359-368.
Roitt et al., Immunology (1998) 4th ed., Mosby, London, pp. 7.7-7.8.
Shantz and Pegg, Int. J. of Biochem. and Cell Biol. (1999) 31:107-122.
Sjogren, Immunotechnology (1997) 3(3):161-172.
Spitler, Cancer Biotherapy (1995) 10:1-3.
Su et al., Proc. Natl. Acad. Sci. USA (1996) 93:7252.
Svaren et al., J. Biol. Chem. (2000) 275(49):38524-38531.
Tao et al., The Journal of Immunology (1989) 143(8):2595-2601.
Verma, Nature (1997) 389:239-242.
Walter et al., Nat. Genetics (1994) 7:22.
Welch et al., Int. J. Cancer (1989) 43:449-457.
White et al., Ann. Rev. Med. (2001) 52:125-145.
Xu Xin et al., FASEB J. (2001) 15:A313.
Supplementary Partial European Search Report for EP 02 73 6898, mailed on Oct. 4, 2005, 4 pages.
MPSRCH Search Report, us-10-001-469a.2866.rag, p. 10.
Madsen et al., Endocrinology (1983) 113(6):2135-2144.
Chen et al., Oncogene (1996) 12:741-751.
Diatchenko et al., PNAS USA (1996) 93(12):6025-6030.
Ji et al., BMC Genomics (2002) 3:12.
Liang et al., Cancer Research (1992) 52:6966-6968.
Watson and Flemming, Cancer Research (1994) 4598-4602.
Afar Daniel E. H.
Faris Mary
Hubert Rene S.
Jakobovits Aya
Mitchell Steven Chappell
Agensys, Inc.
Davis Minh-Tam
Foley Shanon
Morrison & Foerster / LLP
LandOfFree
Antibodies to G protein-coupled receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to G protein-coupled receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to G protein-coupled receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2783743